AR084222A1 - Derivados de amido-piridina como antagonistas del receptor ep4 - Google Patents

Derivados de amido-piridina como antagonistas del receptor ep4

Info

Publication number
AR084222A1
AR084222A1 ARP110104603A ARP110104603A AR084222A1 AR 084222 A1 AR084222 A1 AR 084222A1 AR P110104603 A ARP110104603 A AR P110104603A AR P110104603 A ARP110104603 A AR P110104603A AR 084222 A1 AR084222 A1 AR 084222A1
Authority
AR
Argentina
Prior art keywords
alkane
group
amido
alkanes
halogens
Prior art date
Application number
ARP110104603A
Other languages
English (en)
Inventor
Fabrizio Colace
Manuela Borriello
Lucio Rovati
Luigi Piero Stasi
Benedetta Buzzi
Original Assignee
Rottapharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rottapharm Spa filed Critical Rottapharm Spa
Publication of AR084222A1 publication Critical patent/AR084222A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente relata un derivado de amido-piridina de fórmula (1) o una sal farmacéuticamente aceptada del mismo, donde R1 y R2 son independientemente hidrógenos, alcanos lineales o ramificados C1-3 o conectados formando un anillo de ciclopropano; R es independientemente seleccionado del grupo consistente en halógenos y trifluorometilo y p es 1, 2 ó 3; A es C o N; E es un grupo de fórmula (B) ó (C), donde B es C(O)OH, C(O)O-alcano C1-3, y C es seleccionado del grupo de fórmulas (2); m es 1, 2 ó 3, n es 0 ó 1; W es -O-, -O(alcano C1-3)-; -(alcano C1-3)O-; -C(O)-; -C(=N-O(alcano C1-3))-; -NH- o -NH(alcano C1-3)-; Ar es fenil, opcionalmente sustituido por uno o más sustitutos seleccionados del grupo consistente en halógenos, trifluorometilo, trifluorometoxilo, metilo, -NH(alcano C1-3)-; -N(alcano C1-3)(alcano C1-3)-, un anillo heterocíclico de 5 a 7 miembros que contiene un átomo de nitrógeno el cual está enlazado covalentemente a Ar y opcionalmente conteniendo uno o dos heteroátomos seleccionados de N, O y S; y un anillo heteroaromático de 5- ó 6- miembros que contiene 1 a 3 heteroátomos seleccionados de S, O y N, dicho anillo heteroaromático siendo sustituido por uno o más substitutos seleccionados del grupo consistente de alcanos C1-3, cicloalcoxi C3-5, alcano C1-3carbonilo. Los compuestos de la presente pueden ser usados para la producción de un medicamento para el tratamiento de patologías que requieren el uso de un antagonista de receptor EP4, tales como el tratamiento de dolor agudo y crónico, dolor inflamatorio, osteoartritis, desórdenes asociados a inflamaciones como artritis, artritis reumatoidea, cáncer, endometriosis y migraña.
ARP110104603A 2010-12-10 2011-12-12 Derivados de amido-piridina como antagonistas del receptor ep4 AR084222A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2010/069355 WO2012076063A1 (en) 2010-12-10 2010-12-10 Pyridine amide derivatives as ep4 receptor antagonists

Publications (1)

Publication Number Publication Date
AR084222A1 true AR084222A1 (es) 2013-05-02

Family

ID=43585625

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104603A AR084222A1 (es) 2010-12-10 2011-12-12 Derivados de amido-piridina como antagonistas del receptor ep4

Country Status (7)

Country Link
US (1) US8828987B2 (es)
EP (1) EP2649061B1 (es)
AR (1) AR084222A1 (es)
CA (1) CA2820109C (es)
ES (1) ES2545110T3 (es)
TW (1) TW201307314A (es)
WO (1) WO2012076063A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE043573T2 (hu) 2013-05-17 2019-08-28 Incyte Corp Bipirazol só, amely JAK-gátlóként alkalmazható
CA2914997C (en) 2013-06-12 2021-07-20 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
SI3364958T1 (sl) * 2015-10-23 2023-05-31 Navitor Pharmaceuticals, Inc. Modulatorji interakcije sestrina in gator2 ter njihova uporaba
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
ES2896476T3 (es) * 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
HUE056080T2 (hu) 2017-05-18 2022-01-28 Idorsia Pharmaceuticals Ltd Fenilszármazékok mint PGE2 receptor modulátorok
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
TW201900178A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之嘧啶衍生物
SI3625224T1 (sl) 2017-05-18 2021-11-30 Idorsia Pharmaceuticals Ltd N-substituirani indolni derivati
WO2019161098A1 (en) 2018-02-16 2019-08-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of cytokine-related disorders
JP2021519775A (ja) 2018-03-30 2021-08-12 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤を用いる化膿性汗腺炎の治療
AU2019300449A1 (en) * 2018-07-12 2021-03-04 Rottapharm Biotech S.R.L. (R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-benzoic acid as EP4 receptor antagonist
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
EP4157831A1 (en) 2020-06-02 2023-04-05 Incyte Corporation Processes of preparing a jak1 inhibitor
AU2021329777A1 (en) * 2020-08-18 2023-03-09 Hutchison Medipharma Limited Pyrimidinone compounds and uses thereof
TW202228674A (zh) 2020-11-13 2022-08-01 日商小野藥品工業股份有限公司 藉由併用ｅｐ４拮抗藥與免疫檢查點抑制物質而進行之癌症治療
AU2021396231A1 (en) 2020-12-08 2023-06-22 Incyte Corporation Jak1 pathway inhibitors for the treatment of vitiligo
WO2023041432A1 (en) * 2021-09-14 2023-03-23 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111495A1 (en) 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US6211197B1 (en) * 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
BRPI0414130B8 (pt) 2003-09-03 2021-05-25 Askat Inc compostos de fenilamida ou piridilamida, seu uso e composições farmacêuticas que os compreendem.
BRPI0510598A (pt) 2004-05-04 2007-11-20 Pfizer compostos de amida de aril ou heteroaril substituìdos
WO2005105732A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ｅｐ４受容体アンタゴニストとしてのインドールアミド誘導体
CA2660133C (en) 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
CN101622230B (zh) 2007-02-26 2012-08-22 默克弗罗斯特加拿大有限公司 作为ep4受体拮抗剂的吲哚和二氢吲哚环丙基酰胺衍生物
EP2565191B1 (en) 2008-05-14 2014-10-08 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy

Also Published As

Publication number Publication date
EP2649061A1 (en) 2013-10-16
CA2820109C (en) 2018-01-09
CA2820109A1 (en) 2012-06-14
WO2012076063A1 (en) 2012-06-14
EP2649061B1 (en) 2015-05-13
US20130261100A1 (en) 2013-10-03
US8828987B2 (en) 2014-09-09
ES2545110T3 (es) 2015-09-08
TW201307314A (zh) 2013-02-16

Similar Documents

Publication Publication Date Title
AR084222A1 (es) Derivados de amido-piridina como antagonistas del receptor ep4
GEP20166472B (en) Androgen receptor modulating compounds
EA201591204A2 (ru) НОВЫЕ ХИРАЛЬНЫЕ N-АЦИЛ-5,6,7,(8-ЗАМЕЩЕННЫЕ)-ТЕТРАГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПРИМЕНЕНИЯ ПРИ НАРУШЕНИЯХ, ОПОСРЕДОВАННЫХ NK-3 РЕЦЕПТОРАМИ, И ИХ ХИРАЛЬНЫЙ СИНТЕЗ
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
PE20110854A1 (es) DERIVADOS DE 1-FENIL-1H-PIRAZOLO[3,4-c]PIRIDINA-4-CARBONILAMINA COMO ANTAGONISTAS DE LOS RECEPTORES CCR1
PE20141050A1 (es) Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
AR083831A1 (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
BR112015032637A2 (pt) derivados de pirrolopiridina ou pirazolopiridina
AR077227A1 (es) Compuesto de acido aril/ heteroaril- sustituido carboxilico, su uso para fabricar un medicamento util el tratamiento de afecciones o trastornos mediados por receptores s1p1, tales como esclerosis multiple y composicion farmaceutica que lo comprende
AR066421A1 (es) Compuestos derivados de piridona
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
EA201300122A1 (ru) Циклические n,n'-диарилтиомочевины и n,n'-диарилмочевины - антагонисты андрогеновых рецепторов, противораковое средство, способ получения и применения
ATE530182T1 (de) Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen
CL2012000967A1 (es) Compuestos derivados de amida de los acidos indazol-4-carboxilico y 1-h-pirazolo[3,4-c]piridina-4-carboxilico, agonistas del receptor ccr1; composicion farmaceutica; utiles en el tratamiento de inflamaciones cronicas, alergias, soriasis, artritis reumatoidea, esclerosis multiple, diabetes tipo 1, entre otras.
EA200970704A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ
AR110241A1 (es) Ácidos indanilaminopiridil-ciclopropano-carboxílicos, composiciones farmacéuticas y usos de los mismos
AR092288A1 (es) Ligandos del receptor ep1
RU2017120030A (ru) Новый тип производного цитидина и его применение
TR201910220T4 (tr) Prostat kanserinin tedavisine yönelik ikame edilmiş 2-tiokso-imidazolidin-4-onlar ve bunların spiro analogları, aktif anti-kanser içerik maddesi, farmasötik bileşim, tıbbi preparasyon, yöntem.
RS53940B1 (en) HETEROARYL UNITS AS LIGANDS OF 5-HT4 RECEPTORS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal